Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Non-Current Deffered Revenue: 2015-2023

Historic Non-Current Deffered Revenue for Arrowhead Pharmaceuticals (ARWR) over the last 6 years, with Mar 2023 value amounting to $1.1 million.

  • Arrowhead Pharmaceuticals' Non-Current Deffered Revenue fell 98.80% to $1.1 million in Q1 2023 from the same period last year, while for Mar 2023 it was $1.1 million, marking a year-over-year decrease of 98.80%. This contributed to the annual value of $56.0 million for FY2022, which is 57.45% down from last year.
  • Arrowhead Pharmaceuticals' Non-Current Deffered Revenue amounted to $1.1 million in Q1 2023, which was down 97.36% from $40.8 million recorded in Q4 2022.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Non-Current Deffered Revenue peaked at $131.5 million during Q3 2021, and registered a low of $1.1 million during Q1 2023.
  • Its 3-year average for Non-Current Deffered Revenue is $77.6 million, with a median of $79.7 million in 2021.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Non-Current Deffered Revenue spiked by 1,604.03% in 2019 and then plummeted by 98.80% in 2023.
  • Arrowhead Pharmaceuticals' Non-Current Deffered Revenue (Quarterly) stood at $5.0 million in 2019, then reached $106.5 million in 2021, then crashed by 61.69% to $40.8 million in 2022, then tumbled by 98.80% to $1.1 million in 2023.
  • Its last three reported values are $1.1 million in Q1 2023, $40.8 million for Q4 2022, and $56.0 million during Q3 2022.